FOCUS
Leishmaniasis is a vector-borne infectious disease af ecting the poorest communities around the world and has been designated by the World Health Organization as one of the 17 neglected tropical diseases. Environmental changes such as global warming or human migrations have af ected the vectorreservoir-host triad and led to an expansion of the leishmaniasis geographical range (1) . Leishmaniasis comprises diseases of varied etiologies that are caused by approximately 20 dif erent Leishmania parasite species and are transmitted by nearly 30 medically important sand f y vector species (1) . Mammals including rodents, canids, and in some cases humans are reservoirs of the disease.
Despite the availability of well-characterized animal models that have resulted in a good understanding of the immune response to Leishmania and recognition of correlates of protection from leishmaniasis (2) , an ef cacious human vaccine has eluded us thus far (3) . In this issue of Science Translational Medicine, Das et al. (4) used human cells to select components for a next-generation DNA vaccine, representing a new strategy to make leishmaniasis vaccines for humans.
TOWARD A LEISHMANIASIS VACCINE
Besides the lackluster economic outlook for a leishmaniasis vaccine, there are other inherent challenges facing its development. An ef cacious vaccine for human leishmaniasis must take into account that Leishmania parasites are transmitted by the bite of an insect vector and therefore bypass the skin barrier and its innate protective mechanisms and are also intracellular and inaccessible to antibodies. Unlike most established vaccines, an ef cacious leishmaniasis vaccine must rely on the induction of a robust T cell immunity that overcomes the human and parasite intrinsic variability (2) . T is immunity depends on ef cient presentation of specif c epitopes to T cells by diverse human leukocyte antigen I (HLA-I) and HLA-II molecules present on the surface of antigen-presenting cells. Moreover, to ensure wide coverage, a leishmaniasis vaccine must also take into account the antigenic variability resulting from the existence of multiple Leishmania species and numerous strains.
Despite these challenges, there is consensus in the leishmaniasis scientif c community that a prophylactic vaccine against human leishmaniasis is a viable option (3). Interestingly, in endemic areas, the resolution of cutaneous leishmaniasis (CL) results in life-long protection against the disease. T is notion led to the practice of "leishmanization, " in which controlled inoculation of virulent parasites in discrete parts of the body was used as a live vaccine (3). Historically and to date, this has been the most ef ective way to "immunize" people living in a leishmaniasis-endemic area. However, logistics-including scalability, reproducibility, and transport-combined with the likelihood of adverse events inherent to a live virulent vaccine limits the practicality and acceptability of leishmanization.
Another major limitation facing the f eld of leishmaniasis vaccines has been the inability to move vaccine candidates forward to clinical trials. One main obstacle concerns product development of a vaccine candidate. Despite the existence of a large pool of vaccine candidates against Leishmania, only a few have made it to human clinical trials (3). T ese include f rst-generation killed Leishmania vaccines and two second-generation vaccines, Leish-111f (NCT00121862) and LEISH-F3 (NCT01484548). Unfortunately, the majority of candidates will face the challenge of transitioning from basic research to product implementation, termed the "valley of death" for vaccine development. T is involves multiple technological and f nancial barriers, including issues of scalability, reproducibility, and cost.
THE MAKING OF LEISHDNAVAX
In this issue of Science Translational Medicine, Das et al. addressed the abovementioned challenges in a new strategy for the development of a human leishmaniasis vaccine (4). T is approach began with the selection of seven parasite-derived vaccine candidates known for their ability to induce T cell responses in rodents: KMP11, TSA, CPA, CPB, P74, HASPB, and A2. T ese antigens were further screened for their homology in four Old World parasite species and strains, mostly from human isolates collected from Europe, Africa, and Asia (Fig. 1) . Das and colleagues then tested peripheral blood mononuclear cells (PBMCs) from immune individuals living in Leishmaniaendemic areas to down-select and ref ne these vaccine candidates (4) . T e p r e m i s e for this approach is that individuals cured from visceral leishmaniasis (VL) and CL, or that are asymptomatic for VL, should display a protective T helper 1 (T H 1) immune response toward Leishmania parasites.
T is strategy simultaneously tackled parasite variability and variation of the human T cell immune response to parasite antigens (Fig. 1) .
Using PBMCs from individuals from India, where L. donovani causes VL, and from Tunisia, where L. major and L. tropica cause CL and L. infantum causes VL, the authors stimulated cells with peptide pools derived from f ve of the seven vaccine candidates (Fig. 1) . As expected, the T cell immune response to peptide pools varied among different donors. What was unexpected was the absence of dominant immunogenic peptides in any of the f ve antigens. Instead, the study cohort recognized peptides that spanned the majority of each antigen, likely ref ecting the immunogenicity of the vaccine candidates and the individuality of the human immune response. T is observed variability of the human T cell immune response within a single population brings into focus the pitfalls of vaccine candidate selection solely on the basis of the immunogenicity and protective ef cacy of an antigen in rodent studies.
In By electing to use the MIDGE-T H 1 vector, Das and colleagues have improved the likelihood of success in transitioning LEISHDNAVAX through product development. DNA vaccine production is advantageous owing to its simplicity, reproducibility, adaptability, and low-cost production compared with recombinant proteins. Additionally, DNA vaccination has been shown to be safe in humans (6) .
REVERSE TRANSLATION: FROM HUMANS TO MICE
Having designed LEISHD-NAVAX for immunogenicity in humans, Das et al.
returned to animal modelsin a sense, reverse-translating their research-by testing the ef cacy of LEISHD-NAVAX in a mouse model of VL (Fig. 1) . Immunization of BALB/c mice with LEISHD-NAVAX induced cellular and humoral immune responses to all f ve antigens present in the vaccine. Moreover, compared with controls, vaccinated animals displayed a signif cant reduction in spleen and liver parasitemia 1 month and up to 90 days af er intravenous challenge with 10 million L. donovani parasites. T e parasite burden reduction was dose-dependent, indicating the specif city of the response to LEISHDNAVAX. Upon infection with Leishmania, vaccinated animals showed a signif cant increase in the proinf ammatory T H 1 cytokines interferon-γ and tumor necrosis factor-α but maintained the same level of the anti-inf ammatory cytokines interleukin-10 (IL-10) and IL-4. T is demonstrates the induction of a potent T H 1 immune response by LEISHDNAVAX.
LINGERING QUESTIONS
T e vaccine design adopted by Das et al. (Fig. 1) brings us one step closer to the development of an ef cacious human leish- FOCUS maniasis vaccine. Importantly, although LEISHDNAVAX is targeted to parasites from the Old World, it has the potential to become a pan-Leishmania vaccine. Nevertheless, some aspects require further exploration of LEISHDNAVAX. One question is whether it will induce long-term memory. In the study by Das et al. (4) , the animals were challenged 10 days af er the last immunization, precluding the evaluation of a memory response, which is a prerequisite to the function of an ef cacious vaccine. Ideally, LEISHDNAVAX should be tested in a long-term protection study.
Another question is whether LEISH-DNAVAX will demonstrate protective efcacy in a more relevant animal model that displays disease pathology similar to the one observed in humans, such as hamsters (7) . T e authors elected to use BALB/c mice to test protection against VL. BALB/c mice are considered by many to be a poor animal model for VL because they control the infection and do not show clinical signs of disease (8) . We also have to keep in mind that leishmaniasis is a vector-borne disease and that the contribution of the vector in disease transmission and vaccine development has to be considered. Will LEISHD-NAVAX protect against sand f y-initiated models of infection? Recent studies have highlighted the virulence of vectortransmitted Leishmania parasites that abrogates protection af er needle challenge of vaccinated animals (9) . Such models deliver a more physiological parasite dose and codeposit the Leishmania into the skin alongside established virulence factors present in the infected vector (10), thus better mimicking what occurs naturally.
REFLECTIONS
Currently, there are no vaccines available for prevalent parasitic diseases with high morbidity and mortality such as malaria, tuberculosis, and many others. We can certainly benef t from the fresh look that Das et al. adopted, using humans to make a human vaccine. LEISHDNAVAX came to fruition through the ef orts of a consortium that brought together major researchers from countries endemic and nonendemic for leishmaniasis with expertise in a variety of disciplines and representing academic institutions and private enterprises. T ese partnerships created the critical mass required for such an undertaking. We hope that these partnerships are promoted to develop solutions for other neglected infectious diseases.
